Related Experiment Video
Updated: Aug 5, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
[Immunotherapy and cell therapy in type 1 diabetes : Current state of research]
Sarah Schill1,2, Lena Schwenker3, Franziska Reinmüller3,4
1Institut für Diabetesforschung, Helmholtz Munich, 80939, München, Deutschland. sarah.schill@helmholtz-munich.de.
Background:
Type 1 diabetes begins as an autoimmune disease and can already be diagnosed in the presymptomatic early stage by detecting at least two positive islet autoantibodies (stage 1, International Classification of Diseases, 10th Revision, German Modification [ICD-10-GM]: R76.80; stage 2, ICD-10-GM: R73.00). Immunomodulatory therapies can slow disease progression and delay the clinical manifestation of type 1 diabetes. In parallel, cell therapy for β‑cell replacement is gaining increasing importance as a strategy to restore endogenous insulin production.
Objectives:
This article provides an overview of the current status of immunotherapies and cell therapies in type 1 diabetes.
Materials And Methods:
The review "The future of type 1 diabetes therapy" by Ziegler et al. (2025) served as the basis. In addition, current guidelines, original articles, and selected studies on immunotherapies and β‑cell replacement therapies were considered.
Results:
With teplizumab, the first disease-modifying therapy for stage 2 type 1 diabetes is available. It delays the transition to clinically manifest type 1 diabetes (stage 3) by an average of 2-3 years. Other immunomodulatory therapeutic approaches show preservation of residual β‑cell function in stage 3 type 1 diabetes but are not yet approved for this indication. Stem-cell-based β‑cell replacement therapies are currently being clinically investigated in people with advanced diabetes and impaired awareness of hypoglycemia.
Conclusion:
Immunotherapies and cell therapies mark a paradigm shift in the treatment of type 1 diabetes. In the future, combination therapies will be particularly important to improve the durability of therapeutic effects, as will strategies to protect transplanted cells from alloimmunity and autoimmunity.
More Related Videos
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
Related Concept Videos
Type I Diabetes II: Pathophysiology
Tumor Immunotherapy
Type I Diabetes I: Introduction
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes I: Introduction
EPS and iPS Cells in Disease Research